TFS Capital’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

TFS Capital’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-2,178	Closed	-$282K	–	1047
2016 Q2	$282K	Buy	2,178 +898	+70%	+$100K	0.05%	624
2016 Q1	$120K	Buy	+1,280	New	+$139K	0.02%	865
2015 Q4	–	Sell	-5,907	Closed	-$858K	–	951
2015 Q3	$858K	Buy	+5,907	New	+$1.08M	0.08%	378

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TFS Capital's BLCM Position: Q3 2016 in Review

TFS Capital sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q3 2016, closing a stake of 2,178 shares — an estimated $282K sold.

TFS Capital first reported a position in BLCM in Q3 2015 and held it in 3 quarters. The position peaked at $858K in Q3 2015. 70 funds tracked by Wall St. Rank hold BLCM as of Q3 2016.

TFS Capital reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
TFS Capital sold 2,178 Bellicum Pharmaceuticals, Inc. shares in Q3 2016, an estimated $282K.
TFS Capital first reported a position in Bellicum Pharmaceuticals, Inc. in Q3 2015 and held it in 3 quarters.
TFS Capital's Bellicum Pharmaceuticals, Inc. position peaked at $858K in Q3 2015.
70 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q3 2016.

Based on TFS Capital's 13F filing for Q3 2016, filed 10 Nov 2016.